



Clinical efficacy and safety of *Tripterygium wilfordii* Hook in the treatment of diabetic kidney disease stage IV

A meta-analysis of randomized controlled trials

Daijin Ren, MS^a, Chao Zuo, BS^b, Gaosi Xu, PhD, MD^{a,*}

Abstract

Background: The present study aims to evaluate the clinical efficacy and safety of *Tripterygium wilfordii* Hook (TwH) combined with angiotensin receptor blockers/ACE inhibitors (ARB/ACEI) in the treatment of diabetic kidney disease (DKD) stage IV.

Methods: We searched China National Knowledge Internet (CNKI), the Chinese Biomedical Database, Embase and PubMed for articles about TwH combined with ARB/ACEI in treating DKD stage IV and set the study inclusion and elimination standards.

Results: A total of 22 randomized controlled trials (RCTs) with 1414 participants were collected for detailed evaluation. The metaanalysis results suggested that compared with the controls, the combined group showed significant effects in reducing 24-h urinary protein [mean difference (MD) = -0.87, 95% confidence interval (CI) = (-1.03, -0.71)], raising serum albumin [MD = 4.14, 95% CI (3.43, 4.85)] and the total efficiency [odds ratio (OR) = 4.84, 95% CI (3.33, 7.03)], with no statistical difference in serum creatinine between both groups [MD = -3.02, 95% CI (-6.40, 0.37), P > .05]. However, the risk of adverse reactions increased by 8% [Risk Difference (RD) = 0.08, 95% CI (0.05, 0.11]] in the combination.

Conclusions: TwH combined with ARB/ACEI in the treatment of DKD stage IV is superior to the monotherapy of ARB/ACEI.

Abbreviations: 24 h UPr = 24-hour urinary protein; Alb = serum albumin; ARB/ACEI = angiotensin receptor blockers/ACE inhibitors; DKD = diabetic kidney disease; RCTs = randomized controlled trials; SCr = serum creatinine TwH = *Tripterygium wilfordii* Hook.

Keywords: ACE inhibitors, angiotensin receptor blockers, diabetic kidney disease, randomized controlled trials, *Tripterygium wilfordii* Hook

1. Introduction

Diabetes mellitus (DM) has been increasing at rapid speed. It has been estimated that in 2017 there are 425 million people (aged 20–79) suffering from diabetes worldwide and the number would rise to 629 million in 2045.^[1] DM has become a serious burden and has significant impact on public health.^[2] However, diabetic kidney disease (DKD) is one of the most devastating complications of DM in terms of patients' quality of life and survival,^[3]

Editor: Giovanni Tarantino.

DR and CZ contributed equally to this work.

The authors have no funding and conflicts of interest to disclose.

Supplemental Digital Content is available for this article.

^a Department of Nephrology, the Second Affiliated Hospital of Nanchang University, ^b Grade 2016, the First Clinical Medical College of Nanchang University, China.

* Correspondence: Gaosi Xu, Department of Nephrology, the Second Affiliated Hospital of Nanchang University, No. 1, Minde Road, Donghu District, Nanchang 330006, People's Republic of China (e-mail: gaosixu@163.com).

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

Medicine (2019) 98:11(e14604)

Received: 1 November 2018 / Received in final form: 24 January 2019 / Accepted: 25 January 2019

http://dx.doi.org/10.1097/MD.00000000014604

and DKD is the leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) as well.^[4] Continuous proteinuria has been proved to be a clinical indicator and an independent risk predictor for the progression of DKD,^[5] and utilizing angiotensin receptor blockers/ACE inhibitors (ARB/ACEI) could reduce proteinuria to prevent progression of DKD; however, it is not always adequate to alleviate proteinuria by using currently useful ARB/ACEI, so to prevent further deterioration of DKD, it is urgent for us to find other approaches.^[6]

Tripterygium wilfordii Hook (TwH) has been widely used as a Chinese medicine for many years in many ways, especially in treating glomerulonephritis and organ transplantation.^[7,8] Several trials have been confirmed that TwH markedly attenuated albuminuria and contributed to the prevention of DKD.^[9–11] There is also one meta-analysis about the effect of TwH combined with ARB/ACEI in treating DKD stage IV,^[12] but there is no well-designed meta-analysis of randomized controlled trials (RCTs) at present.

Therefore, we conducted the first meta-analysis of RCTs which included the largest sample size, and we especially aimed to further evaluate the clinical efficacy and safety of TwH combined with ARB/ACEI in treating DKD stage IV.

2. Methods

2.1. Search strategy

We searched China National Knowledge Internet (CNKI), the Chinese Biomedical Database, Embase and PubMed for articles from the establishment of databases to July 2018. The predefined key search terms included "diabetic kidney disease" or "diabetic nephropathy" or "diabetic glomerulosclerosis", and "*Tripterygium wilfordii* Hook" or "tripterygium glycosides" or "triptolide", and "rein-angiotensin" or "ARB" or "ACEI" and "efficacy" or "urinary protein". At the same time, we also reviewed the related research references in order to prevent from neglecting any relevant studies.

2.2. Study criteria

The included criteria for studies were: (1) studies based on RCTs, (2) the patients of the original studies were diagnosed of DKD at clinical stage IV (albuminuria 300 mg/g Cr or more and Estimated Glomerular Filtration Rate (eGFR) is less than 30 ml/min/1.73 m²), (3) the treatment drug was ARB/ACEI alone or ARB/ACEI plus TwH, and (4) the subjects with outcomes included 24-h urinary protein (24 h UPr), serum albumin (Alb), serum creatinine (SCr), total efficiency and adverse reactions. In this meta-analysis, total efficiency was mainly defined as obvious effect plus effective according to Guidelines for clinical research of new Chinese medicine drugs.^[13] Adverse reactions were mainly included: liver function damage, gastrointestinal reactions, myelosuppression, menstrual disorder, etc.

The exclusion criteria were: (1) duplicated publications, (2) studies of patients were not clearly diagnosed or patients with ESRD, tumor, kidney transplantation, acute and chronic nephritis, liver disease and other causes of hypoproteinemia, and (3) studies such as systemic reviews, meta-analysis, case reports, animal experimental studies, etc.

2.3. Data extraction

Data were extracted independently and cross checked by two investigators (Daijin Ren and Chao Zuo). All possible valid references that we searched were checked in detail to identify studies that satisfied the study criteria. Disagreements and differences in inclusion of studies were dealt with by consensus or discussion with a third person (Gaosi Xu). All of reference lists of researches that had been identified were checked out carefully again to prevent the omissions and the details of the selection process are shown in Figure 1.

Data extraction included the first authors' name of the paper, the year of publication, study design, number of patients, the treatment methods were extracted from each of the included papers, course of treatment, urine protein baseline of inclusion criteria and the results for 24 h UPr, Alb, SCr, total efficiency and TwH-related toxicity: details are presented in Supplemental Table 1, http://links.lww.com/MD/C869.

2.4. Quality assessment

The assessment of study quality was performed by using Review Manager (vision 5.3) risk-of-bias tool, including four sections: selection, performance/detection, attrition, and reporting bias (Fig. 2).

2.5. Statistical analysis

The data were abstracted and analyzed by using Review Manager (version 5.3) and STATA (version 12.0, Stata SE). Count data was summarized by forest plot, with expressed as odds ratio (OR) and risk difference (RD) with 95% confidence interval (CI). Measurement data was summarized by forest plot, with expressed as standard mean difference (SMD) and mean difference (MD) with 95% confidence interval (CI). Statistical heterogeneity across the studies was evaluated by the Q statistic and I^2 tests. The heterogeneity is graded according to I^2 thresholds of <25%, 25–75%, and >75%, separately represents low, moderate, and high heterogeneity.^[36] A random-effects model was adopted to process data with heterogeneous results, whereas a fixed-effects model was applied to process data in poor



Figure 1. Study selection flow diagram.

Zhou CL 2013	Zhao RY 2011	Zhang HC 2015	Yun WF 2014	Yang LH 2016	Xu C 2016	Xu BX 2014	Wu YP 2018	Wu SB 2012	Wang ML 2012	Wang JC 2013	Tan YS 2010	Song HX 2005	Pu Y 2013	Li MR 2013	Li J 2011	Li D 2014	Huang NC 2010	Chen XY 2013	Cao QS 2011	Cai XP 2012	Bao HJ 2016	
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	Random sequence generation (selection bias)
••	•	•	~	~	~	~	•	2	~	~	~	~	~	•	~	~	~	->	?	~	~	Allocation concealment (selection bias)
~	•	•	~	~	~	~	•	~	~	~	~	~	~	•	~	~	~	->	~	~	~	Blinding of participants and personnel (performance bias)
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	Blinding of outcome assessment (detection bias)
•	•	•	•	•	•	•	•	•	•	~	•	•	•	•	•	•	•	•	•	~	•	Incomplete outcome data (attrition bias)
•	•	~	•	~	•	•	•	•	•	->	•	•	•	•	•	•	•	•	•	•	•	Selective reporting (reporting bias)
~	•	~	~	~	•	~	~	•	~	~	~	~	~	~	~	•	~	•	~	~	~	Other bias
				_														-	1.1.1			



heterogeneity. It is significant for P < .05 to evaluate all statistical tests. To explore the potential sources of heterogeneity, we analyzed the data by adopting subgroup and sensitivity analysis. Meta-regression was used to analyze and test the potential impact of the characteristics of included studies such as course of treatment, UPr baseline of inclusion criteria and duration of DKD. The publication bias was evaluated by Egger's and Begg's test funnel plots. For the occurrence of zero in the counting data, the automatic default in RevMan 5.3 software is 0.5, which does not affect the results of OR and RD.^[37]

3. Results

3.1. Description of included studies

We identified 22 studies^[14–35] with a total of 1414 (726 patients receiving TwH plus ARB/ACEI versus 688 patients receiving ARB/ACEI) that satisfied our criteria and all cases were treated with routine treatment such as reduce blood glucose and blood press. All the studies were conducted in China. The characteristics of included studies are shown in Supplemental Table S1, http:// links.lww.com/MD/C869. The quality of the 22 studies included based on RevMan 5.3 software risk-of-bias tool was as follows (Fig. 2): all the studies met random sequence generation, and six of them described the specific method of random.^[18,19,24,26,29,33] Four of them referred to patients' informed consent about treatment plan^[21,22,26,33] and others did not report concealed allocation, blinding (participants and personnel). All studies met blinding (outcome assessment). Three of them mentioned the causes of missing and withdrawing cases^[14,30,33] and others did not report incomplete outcome.

3.2. 24-hour urinary protein

Twenty-one trials demonstrated a difference in 24 h proteinuria between the combined and control group.^[14–20,22–35] Three trials reported it after 3 and 6 months of treatment.^[14,19,20] One trial reported it after 1, 2 and 3 months of treatment.^[22] The results were included in RevMan 5.3 software. Heterogeneity testing showed that there was statistically significant difference between the studies (I^2 =89.0%, P<.05). Therefore, the random effect model was adopted. The combined group showed significant effect than the control in reducing the 24 h UPr [MD=-0.87, 95% CI (-1.03, -0.71)].

The subgroups were divided into t > 6 months, t < 6 months, and t < 3 months of combination compared to control treatment

(Fig. 3). There was still obvious heterogeneity within each subgroup [t>6 months: ($I^2=77\%$, P<.05); 3 < t < 6 months: ($I^2=88\%$, P<.05); t<3 months: ($I^2=89\%$, P<.05)]. All subgroups indicated the combined group was superior to the control group in reducing the 24h UPr [t>6 months: SMD=-1.37, 95% CI (-1.73, -1.01); 3 < t < 6 months: SMD=-1.39, 95% CI (-2.03, -0.76); t<3 months: SMD=-1.85, 95% CI (-2.56, -1.14)]. The results revealed that it was more significant in reducing proteinuria for the combined compared to the control when the course of treatment was t<3 months.

We also analyzed a subgroup based on UPr baseline of inclusion criteria (Fig. 4). There was still obvious heterogeneity within each subgroup [>3.5 g/24 h: (P=.09, I^2 =42%); >1.5 g/24 h: (P<.05, I^2 =92%); >1.0 g/24 h: (P<.05, I^2 =84%)]. All subgroups indicated the combined group was superior to the control group in reducing the 24h UPr [>3.5 g/24 h: MD=-1.10, 95% CI (-1.26, -0.94); >1.5 g/24 h: MD=-0.72, 95% CI (-0.97, -0.47); >1.0 g/24 h: MD=-0.63, 95% CI (-1.00, -0.25)]. The results revealed that the combined showed more significant in decreasing proteinuria compared to the control when UPr baseline of inclusion criteria is >3.5 g/24 h.

In addition, we analyzed a subgroup based on TWH combined with ARB or ACEI (Supplemental Figure 1, http://links.lww.com/ MD/C869). There was still obvious heterogeneity within each subgroup [TWH + ARB: (P < .05, $I^2 = 89\%$); TWH + ACEI: (P < .05, $I^2 = 66\%$)]. All subgroups indicated the combined group was superior to the control in reducing the 24h UPr [TWH + ARB: MD = -0.95, 95% CI (-1.13, -0.78); TWH + ACEI: MD = -0.50, 95% CI (-0.74, -0.26)]. The results revealed that TWH combined with ARB had a better effect in reducing proteinuria than combined with ACEI.

Furthermore, we performed a subgroup based on different ways of reducing blood sugar (oral hypoglycemic drugs and/or insulin VS isolated insulin) (Supplemental Figure 2, http://links. lww.com/MD/C869). There was still obvious heterogeneity within each subgroup [oral hypoglycemic drugs and/or insulin: (P < .05, $I^2 = 88\%$); isolated insulin: (P < .05, $I^2 = 88\%$)]. All subgroups indicated the combined group was superior to the control group in reducing the 24h UPr [oral hypoglycemic drugs and/or insulin: MD = -0.93, 95% CI (-1.16, -0.70); isolated insulin: MD = -0.80, 95% CI (-1.18, -0.43)]. The results revealed that the combined showed more significant in decreasing proteinuria compared to the control when way of reducing blood sugar is oral hypoglycemic drugs and/or insulin.

	TwH	ARB/A	CEI	AR	RB/ACE	51		Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV. Random, 95% CI
3.1.1 t≥6months									
Cai XP 2012	1.57	0.73	32	2.91	0.65	29	3.9%	-1.91 [-2.52, -1.30]	
Huang NC 2010	2.34	1.95	25	4.08	3.88	23	3.9%	-0.56 [-1.14, 0.01]	
Li D 2014	1.56	0.74	26	2.92	0.63	27	3.8%	-1.95 [-2.62, -1.29]	
Song HX 2005	0.88	0.31	35	1.23	0.53	32	4.1%	-0.81 [-1.31, -0.31]	
Tan YS 2010	2.34	1.95	25	4.08	3.88	23	3.9%	-0.56 [-1.14, 0.01]	
Wang ML 2012	0.52	0.43	52	1.53	0.59	30	4.0%	-2.03 [-2.58, -1.47]	
Wu SB 2012	1.34	0.78	33	3.01	0.98	32	3.9%	-1.87 [-2.45, -1.28]	
Wu YP 2018	1.7	1.1	34	3	1.6	34	4.0%	-0.94 [-1.44, -0.43]	
Yun WF 2014	1.57	0.73	32	2.91	0.65	29	3.9%	-1.91 [-2.52, -1.30]	
Zhang HC 2015	1.44	1.02	66	3.5	1.94	65	4.2%	-1.32 [-1.70, -0.95]	
Subtotal (95% CI)			360			324	39.6%	-1.37 [-1.73, -1.01]	◆
Heterogeneity: Tau ² =	0.26; Ch	i ² = 39.6	61, df =	9 (P <	0.0000	1); l² =	77%		
Test for overall effect:	Z = 7.44	(P < 0.0	00001)						
3.1.2 3≤t<6months									
Bao HJ 2016	0.95	0.4	26	1.16	0.86	22	3.9%	-0.32 [-0.89, 0.25]	
Cai XP 2012	2.64	0.47	32	3.56	0.38	29	3.8%	-2.11 [-2.75, -1.48]	
Cao QS 2011	1.9	1.1	30	2	0.8	30	4.0%	-0.10 [-0.61, 0.40]	
Li D 2014	2.65	0.46	26	3.57	0.39	27	3.7%	-2.13 [-2.81, -1.45]	
Li J 2011	1.9	0.25	20	2.41	0.73	20	3.8%	-0.92 [-1.57, -0.26]	
Wang JC 2013	0.62	0.43	32	1.27	0.63	32	4.0%	-1.19 [-1.72, -0.66]	
Yun WF 2014	2.64	0.47	32	3.56	0.38	29	3.8%	-2.11 [-2.75, -1.48]	
Zhao RY 2011	1.96	0.24	23	2.59	0.27	23	3.6%	-2.42 [-3.20, -1.65]	
Subtotal (95% CI)			221			212	30.7%	-1.39 [-2.03, -0.76]	-
Heterogeneity: Tau ² =	0.74; Ch	$i^2 = 60.3$	36, df =	• 7 (P <	0.0000	1); l² =	88%		
Test for overall effect:	Z = 4.28	(P < 0.0	0001)						
2424 - 2									
	2 22	0.07	20	0.00	0.44	20	0.70/	4 40 5 0 40 0 701	
Chen XY 2013	3.23	0.37	20	3.82	0.44	20	3.1%	-1.42 [-2.12, -0.72]	
Pu Y 2013	0.46	0.18	98	1.52	0.41	98	4.1%	-3.33 [-3.77, -2.90]	
Xu BX 2014	3.1	0.4	25	3.9	0.6	25	3.8%	-1.54 [-2.18, -0.91]	
Xu C 2016	0.94	0.35	20	2.35	0.81	20	3.5%	-2.21 [-3.02, -1.41]	
These DV 2016	1.13	0.23	14	1.35	0.28	16	3.0%	-0.83 [-1.58, -0.08]	
Zhao RY 2011	2.73	0.32	23	3.45	0.34	23	3.6%	-2.14 [-2.88, -1.41]	
Zhao RY 2011	1.96	0.24	23	2.59	0.27	23	3.0%	-2.42 [-3.20, -1.05]	
Zhou CL 2013 Subtatal (05% CI)	2.4	1.6	15	4	2.4	15	3.0%	-0.76[-1.51, -0.02]	
Subtotal (95% CI)	0.04. 04	2 - 04	230	7 (D 4	0 0000	240	29.1%	-1.05 [-2.50, -1.14]	
Heterogeneity: 1 au* =	0.91; Ch	F = 01.4	49, 01 = 00001	7 (P <	0.0000	1); 1~ =	89%		
rest for overall effect:	2 = 5.12	(P < 0.0	JUUU1)						
Total (95% CI)			819			776	100 0%	-1 52 [-1 85 -1 20]	•
Heterogeneity: Tou ² -	0.62. Ch	i ² - 105	78 4	- 25 (D	< 0.00	001)	2 - 97%		
Test for overall offect:	7 = 0.12	(P<0)	10001	- 20 (P	- 0.00	001), P	- 01 70		-4 -2 0 2 4
Test for subgroup diff	2 - 9.12	$Chi^2 = 1$	13 df	- 2 (P -	- 0.40	12 - 00	4		Favours TwH+ARB/ACEI Favours ARB/ACEI
rest for subdroub diffe	erences:		.43. 01	- 2 (P =	- 0.491	1- = 09	0		

Figure 3. Subgroup analysis of TwH combined with ARB/ACEI in the treatment of DKD stage IV based on the course of treatment, outcome: 24 h UPr.

Finally, we performed meta-regression to explore the source of heterogeneity in Stata 12.0. The effect of reducing proteinuria was not influenced by the course of treatment (P > .851), either in proteinuria baseline of inclusion criteria (P > .46) or the duration of DKD (P > .372).

3.3. Serum albumin

Fifteen trials reported a difference in Alb between the combined and control group.^[14–22,26,28–30,32,35] The only one trial with Alb over 40 g/L after treatment was excluded.^[35] Three trials reported Alb after 3 and 6 months of treatment.^[14,19,20] One trial reported Alb after 1, 2 and 3 months of treatment.^[22] The results were included in RevMan 5.3 software. Statistical heterogeneity analysis indicated moderate heterogeneity across the studies (I^2 =47.0%, P<.05). Therefore, the data was pooled by a random effect model. The combined group was superior to the control group in elevating Alb [MD=4.14, 95% CI (3.43, 4.85)].

We performed subgroup analysis based on the course of treatment (Fig. 5). There was significant heterogeneity between subgroups (P < .05, $I^2 = 91.0\%$). There was no heterogeneity

within each subgroup [t > 6 months: (P = .42, $I^2 = 1.0\%$); 3 < t < 6 months: (P = .80, $I^2 = 0.0\%$); t < 3 months: (P = .86, $I^2 = 0.0\%$)], so it was pooled by a fixed effect model. All subgroups indicated the combined group was superior to the control in elevating Alb [t > 6 months: MD = 5.20, 95% CI (4.41, 6.00); 3 < t < 6 months: MD = 3.69, 95% CI (2.92, 4.46); t < 3 months: MD = 1.93, 95% CI (0.80, 3.06)]. The results revealed that there was a more significant elevation in Alb of the combined group compared to the control when the course of treatment was t > 6 months.

3.4. Serum creatinine

Eighteen trials demonstrated a difference in SCr between the combined and control group.^[14,16,18–22,25–35] Three trials reported SCr after 3 and 6 months of treatment.^[14,19,20] One trial reported SCr after 1, 2 and 3 months of treatment.^[22] The results were included in RevMan 5.3 software. Statistical heterogeneity analysis indicated significant heterogeneity across the studies (I^2 = 83.0%, P < .05). Therefore, the data was pooled by a random effect model. The combined group did not cause SCr elevation compared to the control because there was no

	TwH	+ARB/A	CEI	AF	B/AC	EI		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV. Random, 95% CI
3.2.1 ≥3.5g/24h									
Cai XP 2012	2.64	0.47	32	3.56	0.38	29	5.7%	-0.92 [-1.13, -0.71]	-
Cai XP 2012	1.57	0.73	32	2.91	0.65	29	4.9%	-1.34 [-1.69, -0.99]	
Huang NC 2010	2.34	1.95	25	4.08	3.88	23	0.7%	-1.74 [-3.50, 0.02]	
Li D 2014	2.65	0.46	26	3.57	0.39	27	5.6%	-0.92 [-1.15, -0.69]	-
Li D 2014	1.56	0.74	26	2.92	0.63	27	4.7%	-1.36 [-1.73, -0.99]	
Tan YS 2010	2.34	1.95	25	4.08	3.88	23	0.7%	-1.74 [-3.50, 0.02]	· · · · · · · · · · · · · · · · · · ·
Yun WF 2014	1.57	0.73	32	2.91	0.65	29	4.9%	-1.34 [-1.69, -0.99]	
Yun WF 2014	2.64	0.47	32	3.56	0.38	29	5.7%	-0.92 [-1.13, -0.71]	-
Zhou CL 2013	2.4	1.6	15	4	2.4	15	1.0%	-1.60 [-3.06, -0.14]	
Subtotal (95% CI)			245			231	33.8%	-1.10 [-1.26, -0.94]	♦
Heterogeneity: Tau ² =	0.02; Ch	i² = 13.	87, df =	8 (P =	0.09);	1 ² = 42 ⁰	%		
Test for overall effect:	Z = 13.3	7 (P < 0	0.00001)					
3.2.2 ≥1.5g/24h									
Bao H.I 2016	0.95	0.4	26	1 16	0.86	22	4 6%	-0 21 [-0 60 0 18]	
Chen XX 2013	3 23	0.4	20	3.82	0.44	20	5.5%	-0.59 [-0.84 -0.34]	
Pu V 2013	0.46	0.18	98	1 52	0.41	98	6.3%	-1.06 [-1.15 -0.97]	-
Wu SB 2012	1 34	0.78	33	3.01	0.98	32	4 3%	-1 67 [-2 10 -1 24]	<u> </u>
Yu BX 2014	3 1	0.10	25	3.0	0.00	25	5 3%	-0.80 [-1.08 -0.52]	
Zhao RV 2011	4.06	0.52	23	1 21	0.0	23	5.2%	-0.15 [-0.44 0.14]	
Zhao RV 2011	1.00	0.02	23	2 50	0.40	23	6 1%	0.63[0.78, 0.48]	-
Zhao RV 2011	2 73	0.24	23	3.45	0.21	23	5.8%	-0.03 [-0.70, -0.40]	-
Subtotal (95% CI)	2.75	0.52	271	0.40	0.04	266	43.1%	-0.72 [-0.97 -0.47]	•
Heterogeneity: Tau ² =	0 11· Ch	i ² = 82	76 df =	7 (P <	0 0000	1). 12 =	92%	0.12[0.01, 0.11]	
Test for overall effect:	Z = 5.63	(P < 0.	00001)	1 (1 3	0.0000	,,,	52 /0		
		, .	,						
3.2.3 ≥1.0 g/24h									
Cao QS 2011	1.9	1.1	30	2	0.8	30	3.9%	-0.10 [-0.59, 0.39]	
Li J 2011	1.9	0.25	20	2.41	0.73	20	4.9%	-0.51 [-0.85, -0.17]	
Song HX 2005	0.88	0.31	35	1.23	0.53	32	5.7%	-0.35 [-0.56, -0.14]	
Wang ML 2012	0.52	0.43	52	1.53	0.59	30	5.6%	-1.01 [-1.25, -0.77]	-
Wu YP 2018	1.7	1.1	34	3	1.6	34	3.0%	-1.30 [-1.95, -0.65]	· · ·
Subtotal (95% CI)			171			146	23.1%	-0.63 [-1.00, -0.25]	•
Heterogeneity: Tau ² =	0.14; Ch	i ² = 25.	26, df =	4 (P <	0.0001	l); ² = {	34%		
Test for overall effect:	Z = 3.29	(P = 0.	001)						
Total (95% CI)			687			643	100.0%	-0.85 [-1.00, -0.69]	•
Heterogeneity: Tau ² =	0.10; Ch	i² = 147	7.65, df	= 21 (P	< 0.00	0001): 1	² = 86%		
Test for overall effect:	Z = 10.7	1 (P < 0	0.00001)					
Test for subaroup diffe	erences:	Chi ² = 9	9.38. df	= 2 (P =	0.009	9). ² = 7	78.7%		Favours I writARB/AGEI Favours ARB/AGEI

Figure 4. Subgroup analysis of TwH combined with ARB/ACEI in the treatment of DKD stage IV based on the UPr baseline of inclusion criteria, outcome: 24 h UPr.

significant difference between the combined and the control group [MD=-3.02, 95% CI (-6.40, 0.37), P > .05].

We performed subgroup analysis based on the course of treatment in RevMan 5.3 software (Supplemental Figure 3, http://links.lww.com/MD/C869). There was still significant heterogeneity within each subgroup [t > 6 months: (P < .05, $I^2 = 89.0\%$); 3 < t < 6 months: (P < .05, $I^2 = 82.0\%$); t < 3 months: (P = .16, $I^2 = 37.0\%$)]. All subgroups indicated that there was no significant difference between the combined and the control group [t > 6 months: MD = -5.53, 95% CI (-13.06, 2.00); 3 < t < 6 months: MD = -1.16, 95% CI (-6.28, 3.96); t < 3 months: MD = -1.57, 95% CI (-5.21, 2.06].

3.5. The total efficiency

Twelve trials reported a difference in the total efficiency between the combined and control group.^[14,15,17,19,20,23–25,29,30,33,35] The data was included in RevMan 5.3 software (Fig. 6A). There was no significant statistical heterogeneity in the total efficiency (I^2 =0.0%, P=.52). Thus, the combined odds ratio (OR) was pooled by a fixed effect model. The total efficiency of the combined group was obviously higher than the control [OR= 4.84, 95% CI (3.33, 7.03)].

3.6. Adverse reactions

Thirteen trials reported adverse reactions.^[14–17,21,22,26–33] The combined group reported 25 cases with liver function damage, but recovered after treatment with hepatoprotective drugs and one of them withdrew from the experiment. Eight cases developed gastrointestinal reactions. Leukopenia was observed in three cases. One female had menstrual disorder. The combined reported two cases with hyperkalemia. The results were included in RevMan 5.3 software (Fig. 6B). There was no significant statistical heterogeneity in adverse reactions (I^2 =0.0%, P=.66). Thus, the risk difference (RD) was pooled by a fixed effect model. The adverse reaction was 8% higher in the combined group than the control [RD=0.08, 95% CI (0.05, 0.11)].

3.7. Sensitivity analysis and publication bias

We only performed sensitivity analysis with 24 h UPr and SCr in Stata12.0 software for their significant heterogeneity. Sensitivity analysis indicated that the meta-analysis about them (Supplemental Figures 4 and 5, http://links.lww.com/MD/C869) had low sensitivity and high stability in analysis of patients with DKD stage IV. In order to explore publication bias, we performed Begg's and Egger's test funnel plots with 24 h UPr in Stata12.0

	TwH+	+ARB/A	CEI	AR	B/AC	EI		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% Cl
4.4.1 t≥6months									
Cai XP 2012	31.1	3.89	32	26.2	3.76	29	6.7%	4.90 [2.98, 6.82]	
Huang NC 2010	32.2	6.5	25	24.1	5.8	23	2.0%	8.10 [4.62, 11.58]	· · · · ·
Li D 2014	31.13	3.88	26	26.22	3.74	27	5.8%	4.91 [2.86, 6.96]	
Song HX 2005	37.91	6.03	35	34.98	6.01	32	3.0%	2.93 [0.04, 5.82]	· · · ·
Tan YS 2010	32.2	6.5	25	24.1	5.8	23	2.0%	8.10 [4.62, 11.58]	· · · · ·
Wang ML 2012	32.52	5.62	52	26.97	4.26	30	5.3%	5.55 [3.39, 7.71]	
Wu SB 2012	35.92	5.32	33	30.83	4.22	32	4.5%	5.09 [2.76, 7.42]	
Wu YP 2018	34	6	34	29	6	34	3.0%	5.00 [2.15, 7.85]	
Yun WF 2014	31.1	3.89	32	26.2	3.76	29	6.7%	4.90 [2.98, 6.82]	
Subtotal (95% CI)			294			259	39.0%	5.20 [4.41, 6.00]	•
Heterogeneity: Chi ² =	8.10, df =	= 8 (P =	0.42);	l² = 1%					
Test for overall effect:	Z = 12.8	4 (P < (0.00001)					
4.4.2 3≤t<6months									
Cai XP 2012	26.3	3.4	32	23.1	3.25	29	8.8%	3.20 [1.53, 4.87]	
Li D 2014	26.31	3.38	26	23.08	3.24	27	7.7%	3.23 [1.45, 5.01]	
Li J 2011	35.5	5.6	20	31.9	2.1	20	3.6%	3.60 [0.98, 6.22]	—
Li MR 2013	33.74	5.49	43	28.73	4.01	43	6.0%	5.01 [2.98, 7.04]	
Yun WF 2014	26.3	3.4	32	23.1	3.25	29	8.8%	3.20 [1.53, 4.87]	
Zhao RY 2011	31.92	6.12	23	27.33	5.67	23	2.1%	4.59 [1.18, 8.00]	· · · · ·
Zhou CL 2013	34.6	3.2	15	30.3	3.2	15	4.7%	4.30 [2.01, 6.59]	
Subtotal (95% CI)			191			186	41.7%	3.69 [2.92, 4.46]	•
Heterogeneity: Chi ² =	3.08, df =	= 6 (P =	0.80);	l² = 0%					
Test for overall effect:	Z = 9.43	(P < 0.	00001)						
		• · · · · · · ·							
4.4.3 t<3months									
Xu C 2016	38.2	1.95	20	36.1	2.22	20	14.7%	2.10 [0.81, 3.39]	
Zhao RY 2011	25.96	5.57	23	24.75	5.51	23	2.4%	1.21 [-1.99, 4.41]	
Zhao RY 2011	27.35	5.77	23	25.73	5.76	23	2.2%	1.62 [-1.71, 4.95]	
Subtotal (95% CI)			66			66	19.3%	1.93 [0.80, 3.06]	•
Heterogeneity: Chi ² =	0.29, df =	= 2 (P =	0.86);	l² = 0%				8 5	
Test for overall effect:	Z = 3.36	(P = 0.	(8000						
Total (95% CI)			551			511	100.0%	3.94 [3.45, 4.44]	◆
Heterogeneity: Chi ² =	33.72, df	= 18 (F	P = 0.01); $ ^2 = 4$	7%				
Test for overall effect:	Z = 15.5	8 (P < (0.00001)					
Test for subaroup diffe	erences:	Chi ² = 2	22.24. d	f = 2 (P	< 0.00)01). I²	= 91.0%		Favours ARB/AGEL Favours IWH+ARB/AGEL
Figure 5 Subgroup	analysis	of Twł	-l comh	nined w	ith AF		I in the t	reatment of DKD sta	age IV based on the course of treatment, outcome. Alb

software (Supplemental Figure 6, http://links.lww.com/MD/C869). The Begg's test (Pr > |z| = 0.098) and the Egger's linear regression test (P > .792), which indicated that there was no evidence of substantial publication bias and the included studies were all small sample RCTs.

4. Discussion

DKD is the leading cause of ESRD^[4] and one of the most important prognostic factor for its progression is persistent proteinuria.^[5] As a result, reducing proteinuria level has been considered as a goal of DKD treatment. The benefit of reducing proteinuria by using ARB/ACEI is valid. However, the use of ARB/ACEI is not always enough to alleviate proteinuria, so other approaches have been put forward, for example, inflammation, oxidative stress and immune reactions have become quite significant as targets for new treatments.^[6] TwH as a medicinal plant has been used for immune and inflammatory diseases in China to ameliorate proteinuria and prevent DKD by exerting immunosuppressive, anti-inflammatory, anti- oxidative stress and podocyte-protective effects.^[9–11,38,39] Therefore, it is necessary to explore the efficacy and safety of TwH combined with ARB/ACEI in treating DKD.

In the present meta-analysis, we found the combined group showed significant effects in reducing proteinuria and increasing the total efficiency but the risk of adverse reactions is higher than the control, which is the same as another meta-analysis.^[12] Furthermore, we found the combined showed significant effects in elevating Alb compared to the control, with no statistical difference in SCr. But in order to explore the heterogeneity of the meta-analysis, we performed different subgroup analyses in the process of analyzing different outcomes and there are also some original conclusions: (1) when the course of treatment is <3months, the speed of reducing proteinuria is the fastest. Several studies mentioned the greatest reduction in proteinuria with ARB/ACEI used alone was obvious during the first 6.5 or 6 to 12 months and persisted for the remainder of the trial.^[40,41] Therefore, we could draw a conclusion that TwH may help ARB/ACEI accelerate the speed of reducing proteinuria. But a trial mentioned that the greatest reduction in proteinuria was not clear.^[42] So there are needed lots of trials to confirm it, (2) When UPr baseline of inclusion criteria is >3.5 g/24 h, the combined showed more significant effect in reducing proteinuria compared to the control, (3) TWH combined with ARB showed better effect in reducing proteinuria than TWH combined with ACEI, that is, ARB is better than ACEI in reducing proteinuria, which has been confirmed in a trial, Pathak JV et al.,^[43] (4) When way of reducing blood sugar is oral hypoglycemic drugs and/or insulin, the combined showed more significant effect in reducing proteinuria compared to the control, (5) the combined group in elevating Alb is better than the control and the longer the course of treatment, the more the elevation of Alb, (6) the

	TwH+ARB	ACE!	ARB/A	CEI		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% CI
Cai XP 2012	28	32	20	29	9.6%	3.15 [0.85, 11.68]	
Chen XY 2013	20	20	17	20	1.5%	8.20 [0.40, 169.90]	
Huang NC 2010	18	25	4	23	4.3%	12.21 [3.05, 48.91]	
Li D 2014	23	26	22	27	9.1%	1.74 [0.37, 8.18]	
Li J 2011	17	20	15	20	8.2%	1.89 [0.38, 9.27]	
Pu Y 2013	91	98	68	98	17.7%	5.74 [2.38, 13.84]	_ _
Tan YS 2010	18	25	4	23	4.3%	12.21 [3.05, 48.91]	
Wang JC 2013	30	32	23	32	5.2%	5.87 [1.16, 29.83]	
Wu SB 2012	24	33	14	32	14.1%	3.43 [1.22, 9.67]	
Xu BX 2014	19	25	13	25	11.4%	2.92 [0.87, 9.78]	
Yun WF 2014	28	32	20	29	9.6%	3.15 [0.85, 11.68]	
Zhang HC 2015	64	66	45	62	5.1%	12.09 [2.66, 54.94]	
			1000				1.52
Total (95% CI)		434		420	100.0%	4.84 [3.33, 7.03]	•
Total events	380		265				
Heterogeneity: Chi ² = 1	0.08, df = 11	(P = 0.5)	52); l ² = 09	%			
Test for overall effect: Z	z = 8.28 (P <	0.00001)				
А							Tavouis AND/AGEL Tavouis TwittAND/AGEL
	Translation of the second			<u> </u>		Dial Difference	Diel, Differences
Study or Subgroup	TwH+ARB	/ACEI	ARB/A	CEI	Waight	Risk Difference	Risk Difference
Study or Subgroup	TwH+ARB Events	ACEI Total	ARB/A Events	CEI Total	Weight	Risk Difference M-H, Fixed, 95% Cl	Risk Difference M-H, Fixed, 95% Cl
Study or Subgroup Bao HJ 2016	TwH+ARB Events 0	/ACEI Total 26	ARB/A Events	CEI Total 22	Weight 5.5%	Risk Difference <u>M-H, Fixed, 95% CI</u> 0.00 [-0.08, 0.08]	Risk Difference M-H, Fixed, 95% Cl
Study or Subgroup Bao HJ 2016 Cai XP 2012	TwH+ARB Events 0 2	/ACEI <u>Total</u> 26 35 20	ARB/A Events 0 0	CEI <u>Total</u> 22 30 20	Weight 5.5% 7.4%	Risk Difference <u>M-H. Fixed, 95% CI</u> 0.00 [-0.08, 0.08] 0.06 [-0.04, 0.15] 0.05 [-0.05 0.42]	Risk Difference M-H, Fixed, 95% Cl
Study or Subgroup Bao HJ 2016 Cai XP 2012 Cao QS 2011	TwH+ARB Events 0 2 1	/ACEI <u>Total</u> 26 35 30	ARB/A Events 0 0 0	CEI <u>Total</u> 22 30 30	Weight 5.5% 7.4% 6.9%	Risk Difference <u>M-H. Fixed, 95% CI</u> 0.00 [-0.08, 0.08] 0.06 [-0.04, 0.15] 0.03 [-0.05, 0.12] 0.00 [-0.00 00]	Risk Difference M-H, Fixed, 95% Cl
Study or Subgroup Bao HJ 2016 Cai XP 2012 Cao QS 2011 Huang NC 2010	TwH+ARB Events 0 2 1 3	/ACEI <u>Total</u> 26 35 30 25 20	ARB/A Events 0 0 0 0	CEI <u>Total</u> 22 30 30 23 20	Weight 5.5% 7.4% 6.9% 5.5%	Risk Difference <u>M-H, Fixed, 95% CI</u> 0.00 [-0.08, 0.08] 0.06 [-0.04, 0.15] 0.03 [-0.05, 0.12] 0.12 [-0.02, 0.26] 0.00 [-0.05, 0.05]	Risk Difference M-H, Fixed, 95% Cl
Study or Subgroup Bao HJ 2016 Cai XP 2012 Cao QS 2011 Huang NC 2010 Li J 2011	TwH+ARB Events 0 2 1 3 2	/ACEI <u>Total</u> 26 35 30 25 20 10	ARB/A <u>Events</u> 0 0 0 0 0	CEI <u>Total</u> 22 30 30 23 20 40	Weight 5.5% 7.4% 6.9% 5.5% 4.6%	Risk Difference <u>M-H, Fixed, 95% CI</u> 0.00 [-0.08, 0.08] 0.06 [-0.04, 0.15] 0.03 [-0.05, 0.12] 0.12 [-0.02, 0.26] 0.10 [-0.05, 0.25]	Risk Difference M-H, Fixed, 95% Cl
Study or Subgroup Bao HJ 2016 Cai XP 2012 Cao QS 2011 Huang NC 2010 Li J 2011 Li MR 2013	TwH+ARB Events 0 2 1 3 2 1	/ACEI <u>Total</u> 26 35 30 25 20 43 55	ARB/A <u>Events</u> 0 0 0 0 0 0 0	CEI <u>Total</u> 22 30 30 23 20 43 20	Weight 5.5% 7.4% 6.9% 5.5% 4.6% 9.9%	Risk Difference <u>M-H, Fixed, 95% CI</u> 0.00 [-0.08, 0.08] 0.06 [-0.04, 0.15] 0.03 [-0.05, 0.12] 0.12 [-0.02, 0.26] 0.10 [-0.05, 0.25] 0.02 [-0.04, 0.09]	Risk Difference M-H, Fixed, 95% Cl
Study or Subgroup Bao HJ 2016 Cai XP 2012 Cao QS 2011 Huang NC 2010 Li J 2011 Li MR 2013 Tan YS 2010	TwH+ARB <u>Events</u> 0 2 1 3 2 1 3 2	/ACEI <u>Total</u> 26 35 30 25 20 43 25 25 20 43 25 25 25 20 25 20 25 20 25 25 20 25 25 20 25 25 25 25 25 25 25 25 25 25	ARB/A <u>Events</u> 0 0 0 0 0 0 0 0 0 0 0 0 0	CEI <u>Total</u> 22 30 23 20 43 23 23 20 43 23 23 23 23 23 23 23 23 20 20 20 20 20 20 20 20 20 20	Weight 5.5% 7.4% 6.9% 5.5% 4.6% 9.9% 5.5%	Risk Difference <u>M-H, Fixed, 95% CI</u> 0.00 [-0.08, 0.08] 0.06 [-0.04, 0.15] 0.03 [-0.05, 0.12] 0.12 [-0.02, 0.26] 0.10 [-0.05, 0.25] 0.02 [-0.04, 0.09] 0.12 [-0.02, 0.26]	Risk Difference M-H, Fixed, 95% Cl
Study or Subgroup Bao HJ 2016 Cai XP 2012 Cao QS 2011 Huang NC 2010 Li J 2011 Li MR 2013 Tan YS 2010 Wang ML 2012	TwH+ARB <u>Events</u> 0 2 1 3 2 1 3 3 3 2	/ACEI Total 26 35 30 25 20 43 25 52 52	ARB/A <u>Events</u> 0 0 0 0 0 0 0 0 0 0 0 0 0	CEI Total 22 30 23 20 43 23 20 43 23 30 23 20 43 23 20 43 23 20 43 23 20 23 20 23 20 23 20 23 20 23 20 23 20 23 20 23 20 23 20 23 20 23 20 23 20 23 20 23 20 23 20 23 20 23 20 23 20 20 20 20 20 20 20 20 20 20	Weight 5.5% 7.4% 6.9% 5.5% 4.6% 9.9% 5.5% 8.8%	Risk Difference M-H, Fixed, 95% CI 0.00 [-0.08, 0.08] 0.06 [-0.04, 0.15] 0.03 [-0.05, 0.12] 0.12 [-0.02, 0.26] 0.10 [-0.05, 0.25] 0.02 [-0.04, 0.09] 0.12 [-0.02, 0.26] 0.06 [-0.02, 0.14] 0.00 [-0.02, 0.14]	Risk Difference M-H, Fixed, 95% Cl
Study or Subgroup Bao HJ 2016 Cai XP 2012 Cao QS 2011 Huang NC 2010 Li J 2011 Li MR 2013 Tan YS 2010 Wang ML 2012 Wu SB 2012	TwH+ARB <u>Events</u> 0 2 1 3 2 1 3 3 3 3 4	/ACEI Total 26 35 30 25 20 43 25 52 33 33	ARB/A <u>Events</u> 0 0 0 0 0 0 0 0 0 0 0 0 0	CEI Total 22 30 23 20 43 23 30 32	Weight 5.5% 7.4% 6.9% 5.5% 4.6% 9.9% 5.5% 8.8% 7.5%	Risk Difference M-H, Fixed, 95% Cl 0.00 [-0.08, 0.08] 0.06 [-0.04, 0.15] 0.03 [-0.05, 0.12] 0.12 [-0.02, 0.26] 0.02 [-0.04, 0.09] 0.12 [-0.02, 0.26] 0.06 [-0.02, 0.14] 0.09 [-0.02, 0.20]	Risk Difference M-H, Fixed, 95% Cl
Study or Subgroup Bao HJ 2016 Cai XP 2012 Cao QS 2011 Huang NC 2010 Li J 2011 Li MR 2013 Tan YS 2010 Wang ML 2012 Wu SB 2012 Wu YP 2018	TwH+ARB <u>Events</u> 0 2 1 3 2 1 3 3 3 4 2	/ACEI Total 26 35 30 25 20 43 25 52 33 34 26	ARB/A <u>Events</u> 0 0 0 0 0 0 0 0 0 0 0 2 2	CEI Total 22 30 23 20 43 23 30 32 30 32 32 32 32 32 32 32 32 32 32	Weight 5.5% 7.4% 6.9% 5.5% 4.6% 9.9% 5.5% 8.8% 7.5% 7.5% 7.8%	Risk Difference M-H, Fixed, 95% Cl 0.00 [-0.08, 0.08] 0.06 [-0.04, 0.15] 0.03 [-0.05, 0.12] 0.12 [-0.02, 0.26] 0.10 [-0.05, 0.25] 0.02 [-0.04, 0.09] 0.12 [-0.02, 0.26] 0.06 [-0.02, 0.14] 0.09 [-0.02, 0.20] 0.06 [-0.08, 0.19]	Risk Difference M-H, Fixed, 95% Cl
Study or Subgroup Bao HJ 2016 Cai XP 2012 Cao QS 2011 Huang NC 2010 Li J 2011 Li MR 2013 Tan YS 2010 Wang ML 2012 Wu SB 2012 Wu YP 2018 Xu C 2016	TwH+ARB <u>Events</u> 0 2 1 3 2 1 3 3 3 4 3 4 3 4 3	/ACEI Total 26 35 30 25 20 43 25 52 33 34 20 20	ARB/A <u>Events</u> 0 0 0 0 0 0 0 0 0 0 0 0 0	CEI Total 22 30 23 20 43 20 43 23 30 32 34 20 32 34 20 32 34 20 32 30 32 30 32 30 30 30 30 30 30 30 30 30 30	Weight 5.5% 7.4% 6.9% 5.5% 4.6% 9.9% 5.5% 8.8% 7.5% 7.8% 4.6%	Risk Difference M-H, Fixed, 95% Cl 0.00 [-0.08, 0.08] 0.06 [-0.04, 0.15] 0.03 [-0.05, 0.12] 0.12 [-0.02, 0.26] 0.02 [-0.04, 0.09] 0.12 [-0.02, 0.26] 0.06 [-0.02, 0.14] 0.09 [-0.02, 0.20] 0.06 [-0.08, 0.19] 0.15 [-0.02, 0.32]	Risk Difference M-H, Fixed, 95% Cl
Study or Subgroup Bao HJ 2016 Cai XP 2012 Cao QS 2011 Huang NC 2010 Li J 2011 Li MR 2013 Tan YS 2010 Wang ML 2012 Wu SB 2012 Wu YP 2018 Xu C 2016 Zhang HC 2015	TwH+ARB <u>Events</u> 0 2 1 3 2 1 3 3 3 4 3 9 0	/ACEI <u>Total</u> 26 35 30 25 20 43 25 52 33 34 20 79	ARB/A Events 0 0 0 0 0 0 0 0 0 0 0 0 0	CEI Total 22 30 23 20 43 20 43 23 30 32 34 20 34 20 70 70 70 70 70 70 70 70 70 7	Weight 5.5% 7.4% 6.9% 5.5% 9.9% 5.5% 8.8% 7.5% 7.8% 4.6% 17.1%	Risk Difference M-H, Fixed, 95% Cl 0.00 [-0.08, 0.08] 0.06 [-0.04, 0.15] 0.03 [-0.05, 0.12] 0.12 [-0.02, 0.26] 0.02 [-0.04, 0.09] 0.12 [-0.02, 0.26] 0.06 [-0.02, 0.14] 0.09 [-0.02, 0.20] 0.06 [-0.08, 0.19] 0.15 [-0.02, 0.32] 0.11 [0.04, 0.19]	Risk Difference M-H, Fixed, 95% Cl
Study or Subgroup Bao HJ 2016 Cai XP 2012 Cao QS 2011 Huang NC 2010 Li J 2011 Li MR 2013 Tan YS 2010 Wang ML 2012 Wu SB 2012 Wu YP 2018 Xu C 2016 Zhang HC 2015 Zhao RY 2011	TwH+ARB <u>Events</u> 0 2 1 3 2 1 3 3 3 4 3 9 2 1	/ACEI <u>Total</u> 26 35 30 25 20 43 25 52 33 34 20 79 23 34	ARB/A Events 0 0 0 0 0 0 0 0 0 0 0 0 0	CEI Total 22 30 23 20 43 20 43 20 43 20 32 34 20 70 23 23 32 34 20 70 23 23 34 20 23 23 23 23 20 23 20 23 23 23 20 23 23 23 23 23 23 23 23 23 23	Weight 5.5% 7.4% 6.9% 5.5% 4.6% 5.5% 8.8% 7.5% 7.8% 4.6% 17.1% 5.3%	Risk Difference M-H, Fixed, 95% CI 0.00 [-0.08, 0.08] 0.06 [-0.04, 0.15] 0.03 [-0.05, 0.12] 0.12 [-0.02, 0.26] 0.02 [-0.04, 0.09] 0.12 [-0.02, 0.26] 0.06 [-0.02, 0.14] 0.09 [-0.02, 0.20] 0.06 [-0.08, 0.19] 0.15 [-0.02, 0.32] 0.11 [0.04, 0.19] 0.09 [-0.05, 0.22]	Risk Difference M-H, Fixed, 95% Cl
Study or Subgroup Bao HJ 2016 Cai XP 2012 Cao QS 2011 Huang NC 2010 Li J 2011 Li MR 2013 Tan YS 2010 Wang ML 2012 Wu SB 2012 Wu YP 2018 Xu C 2016 Zhang HC 2015 Zhao RY 2011 Zhou CL 2013	TwH+ARB <u>Events</u> 0 2 1 3 2 1 3 3 4 3 4 3 9 2 1 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 3 1 3 3 1 3 3 3 4 3 1 3 3 1 3 3 1 3 3 3 1 3 3 1 3 3 3 4 3 3 1 3 3 3 4 3 3 1 3 3 3 4 3 3 4 3 3 4 3 3 4 3 3 4 3 3 4 3 3 4 3 3 4 3 3 4 3 3 4 3 3 4 3 3 4 3 3 4 3 9 2 1 1 1 3 3 3 4 3 3 3 3 3 4 3 3 3 4 3 3 3 4 3 3 3 4 3 3 1 3 3 4 3 3 4 3 3 2 1 3 3 3 4 3 3 3 4 3 3 2 1 1 3 3 3 4 3 3 2 1 1 3 3 3 3 3 4 3 2 1 1 3 3 2 1 1 3 3 3 4 3 3 2 1 1 1 1 1 1 1 1 1 1 1 1 1	/ACEI <u>Total</u> 26 35 30 25 20 43 25 52 33 34 20 79 23 15	ARB/A Events 0 0 0 0 0 0 0 0 0 0 0 0 0	CEI Total 22 30 23 20 43 20 43 23 30 32 34 20 70 23 15	Weight 5.5% 7.4% 6.9% 5.5% 8.8% 7.5% 8.8% 7.5% 4.6% 17.1% 5.3% 3.5%	Risk Difference M-H, Fixed, 95% Cl 0.00 [-0.08, 0.08] 0.06 [-0.04, 0.15] 0.03 [-0.05, 0.12] 0.12 [-0.02, 0.26] 0.02 [-0.04, 0.09] 0.12 [-0.02, 0.26] 0.06 [-0.02, 0.14] 0.09 [-0.02, 0.20] 0.06 [-0.08, 0.19] 0.15 [-0.02, 0.32] 0.11 [0.04, 0.19] 0.09 [-0.05, 0.22] 0.07 [-0.10, 0.23]	Risk Difference M-H, Fixed, 95% Cl
Study or Subgroup Bao HJ 2016 Cai XP 2012 Cao QS 2011 Huang NC 2010 Li J 2011 Li MR 2013 Tan YS 2010 Wang ML 2012 Wu SB 2012 Wu YP 2018 Xu C 2016 Zhang HC 2015 Zhao RY 2011 Zhou CL 2013 Total (95% CI)	TwH+ARB <u>Events</u> 0 2 1 3 2 1 3 3 3 4 3 9 2 1 1 3 1 3 1 3 3 4 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 3 1 3 3 3 4 3 1 3 3 3 4 3 3 4 3 3 4 3 3 3 4 3 3 4 3 3 3 4 3 3 4 3 3 3 4 3 3 3 4 3 3 3 4 3 3 4 3 3 4 3 3 4 3 3 4 3 3 4 3 3 4 3 3 4 3 3 4 3 3 4 3 3 4 3 3 4 3 3 4 3 3 4 3 9 2 1 1 3 3 3 4 3 3 4 3 3 3 4 3 3 3 4 3 3 3 4 3 3 4 3 3 3 4 3 3 4 3 3 4 3 3 3 4 3 3 3 3 4 3 3 3 4 3 3 3 4 3 3 3 3 3 4 3 3 3 4 3 3 3 4 3 3 3 4 3 3 3 4 3 3 3 4 3 3 3 4 5 1 1 1 1 1 1 1 1 1 1 1 1 1	/ACEI Total 26 35 20 43 25 52 33 34 20 79 23 15 460	ARB/A Events 0 0 0 0 0 0 0 0 0 0 0 0 0	CEI Total 22 30 23 20 43 20 43 20 43 30 32 34 20 32 34 20 32 34 20 32 34 20 32 34 20 35 30 32 30 32 30 32 30 32 30 32 30 30 32 30 30 32 30 30 32 30 30 30 30 30 30 30 30 30 30	Weight 5.5% 7.4% 6.9% 5.5% 4.6% 7.5% 7.8% 4.6% 17.1% 5.3% 3.5% 100.0%	Risk Difference M-H, Fixed, 95% Cl 0.00 [-0.08, 0.08] 0.06 [-0.04, 0.15] 0.03 [-0.05, 0.12] 0.12 [-0.02, 0.26] 0.10 [-0.05, 0.25] 0.02 [-0.04, 0.09] 0.12 [-0.02, 0.26] 0.06 [-0.02, 0.14] 0.09 [-0.02, 0.20] 0.06 [-0.08, 0.19] 0.15 [-0.02, 0.32] 0.11 [0.04, 0.19] 0.09 [-0.05, 0.22] 0.07 [-0.10, 0.23] 0.08 [0.05, 0.11]	Risk Difference M-H, Fixed, 95% Cl
Study or Subgroup Bao HJ 2016 Cai XP 2012 Cao QS 2011 Huang NC 2010 Li J 2011 Li MR 2013 Tan YS 2010 Wang ML 2012 Wu SB 2012 Wu YP 2018 Xu C 2016 Zhang HC 2015 Zhao RY 2011 Zhou CL 2013 Total (95% CI) Total events	TwH+ARB <u>Events</u> 0 2 1 3 2 1 3 3 4 3 9 2 1 3 3 4 3 3 4 3 3 4 3 3 4 3 3 4 3 3 4 3 3 3 4 3 3 3 4 3 3 3 4 3 3 3 3 4 3 3 3 3 4 3 3 3 3 4 3 3 3 3 3 3 4 3 3 3 3 3 3 3 3 3 3 3 3 3	/ACEI Total 26 35 30 25 20 43 25 52 33 34 20 79 23 15 460	ARB/A <u>Events</u> 0 0 0 0 0 0 0 0 0 0 0 0 0	CEI Total 22 30 23 20 43 20 43 20 43 20 43 20 43 20 32 34 20 32 34 20 32 34 20 32 34 20 35 43 30 32 34 30 32 32 34 30 32 32 34 30 32 34 30 32 34 30 32 34 30 32 34 30 32 34 34 30 32 34 34 35 36 36 32 34 35 36 36 36 32 35 34 35 35 35 35 35 35 35 35 35 35	Weight 5.5% 7.4% 6.9% 5.5% 8.8% 7.5% 8.8% 7.5% 7.8% 4.6% 17.1% 5.3% 3.5%	Risk Difference M-H, Fixed, 95% Cl 0.00 [-0.08, 0.08] 0.06 [-0.04, 0.15] 0.03 [-0.05, 0.12] 0.12 [-0.02, 0.26] 0.10 [-0.05, 0.25] 0.02 [-0.04, 0.09] 0.12 [-0.02, 0.26] 0.06 [-0.02, 0.14] 0.09 [-0.02, 0.20] 0.06 [-0.08, 0.19] 0.15 [-0.02, 0.32] 0.11 [0.04, 0.19] 0.09 [-0.05, 0.22] 0.07 [-0.10, 0.23] 0.08 [0.05, 0.11]	Risk Difference M-H, Fixed, 95% Cl
Study or Subgroup Bao HJ 2016 Cai XP 2012 Cao QS 2011 Huang NC 2010 Li J 2011 Li MR 2013 Tan YS 2010 Wang ML 2012 Wu SB 2012 Wu YP 2018 Xu C 2016 Zhang HC 2015 Zhao RY 2011 Zhou CL 2013 Total (95% CI) Total events Heterogeneity: Chi² = 1	TwH+ARB <u>Events</u> 0 2 1 3 2 1 3 3 4 3 9 2 1 3 3 4 3 9 2 1 3 3 4 3 9 2 1 3 3 4 3 9 2 1 3 3 4 3 3 4 3 9 2 1 3 3 4 3 3 4 3 9 2 1 3 3 3 4 3 9 2 1 3 3 3 4 3 3 3 4 3 3 4 3 3 4 3 9 2 1 3 3 3 4 3 3 3 4 3 3 4 3 3 4 3 9 2 1 1 3 3 3 4 3 3 4 3 9 2 1 1 3 3 4 3 9 2 1 1 3 3 4 3 3 9 2 1 1 3 3 4 3 3 9 2 1 1 3 3 3 4 3 3 3 4 3 3 4 3 3 3 4 3 3 3 4 3 3 3 4 3 3 3 4 3 3 3 4 3 3 3 4 3 3 3 4 3 3 3 4 3 3 3 4 3 3 3 4 3 3 3 3 3 3 4 3 3 3 3 3 3 3 3 3 3 3 3 3	/ACEI <u>Total</u> 26 35 30 25 20 43 25 52 33 34 20 79 23 15 460 8 (P = 0.6	ARB/A <u>Events</u> 0 0 0 0 0 0 0 0 0 0 0 0 0	CEI Total 22 30 23 20 43 23 30 32 34 20 70 23 15 415	Weight 5.5% 7.4% 6.9% 5.5% 8.8% 7.5% 8.8% 7.5% 4.6% 17.1% 5.3% 3.5% 100.0%	Risk Difference M-H, Fixed, 95% Cl 0.00 [-0.08, 0.08] 0.06 [-0.04, 0.15] 0.03 [-0.05, 0.12] 0.12 [-0.02, 0.26] 0.02 [-0.04, 0.09] 0.12 [-0.02, 0.26] 0.06 [-0.02, 0.14] 0.09 [-0.02, 0.20] 0.06 [-0.08, 0.19] 0.15 [-0.02, 0.32] 0.11 [0.04, 0.19] 0.09 [-0.05, 0.22] 0.07 [-0.10, 0.23] 0.08 [0.05, 0.11]	Risk Difference M-H, Fixed, 95% Cl
Study or Subgroup Bao HJ 2016 Cai XP 2012 Cao QS 2011 Huang NC 2010 Li J 2011 Li MR 2013 Tan YS 2010 Wang ML 2012 Wu SB 2012 Wu YP 2018 Xu C 2016 Zhang HC 2015 Zhao RY 2011 Zhou CL 2013 Total (95% CI) Total events Heterogeneity: Chi² = 1 Test for overall effect: 2	TwH+ARB <u>Events</u> 0 2 1 3 2 1 3 3 4 3 3 4 3 9 2 1 3 7 0.46, df = 13 2 2 4.99 (P <	/ACEI <u>Total</u> 26 35 30 25 20 43 25 52 33 34 20 79 23 15 460 8 (P = 0.6 0.00001	ARB/A <u>Events</u> 0 0 0 0 0 0 0 0 0 0 0 0 0	CEI Total 22 30 23 23 23 23 23 23 43 23 30 32 34 20 70 23 31 5 415 %	Weight 5.5% 7.4% 6.9% 5.5% 8.8% 7.5% 7.8% 4.6% 17.1% 5.3% 3.5% 100.0%	Risk Difference M-H, Fixed, 95% Cl 0.00 [-0.08, 0.08] 0.06 [-0.04, 0.15] 0.03 [-0.05, 0.12] 0.12 [-0.02, 0.26] 0.02 [-0.04, 0.09] 0.12 [-0.02, 0.26] 0.06 [-0.02, 0.14] 0.09 [-0.02, 0.20] 0.06 [-0.08, 0.19] 0.15 [-0.02, 0.32] 0.11 [0.04, 0.19] 0.09 [-0.05, 0.22] 0.07 [-0.10, 0.23] 0.08 [0.05, 0.11]	Risk Difference M-H, Fixed, 95% Cl



combined group does not cause serum creatinine elevation compared to the control, and (7) the risk of adverse reactions (mainly are liver function damage, gastrointestinal reaction, or menstrual disorders) was 8% higher in the combined group than the control, but adverse reactions are mild and do not influence the trial. We also performed meta-regression in the process of analyzing proteinuria including three variables, which were not heterogenous. The sensitivity analysis was carried out with 24h Upr and SCr, which showed that our meta-analysis had low sensitivity and high stability, the Begg's and the Egger's test funnel plots with 24h UPr showed no publication bias.

There were several limitations in this meta-analysis: (1) all the studies were small sample studies, (2) the included literatures lacked some data that might affect urinary protein, such as Body Mass Index (BMI), blood pressure control and etc, so that we could not analyze their effects on proteinuria, (3) there was no specific oral hypoglycemic drug or insulin in the included studies, (4) only Chinese and English studies were included in this meta-analysis, (5) significant statistical heterogeneity still existed in the included studies and should be further explored, and (6) some dosage of TwH was not uniform.

In conclusion, TwH combined with ARB/ACEI in the treatment of DKD stage IV shows significant effects than the monotherapy of ARB/ACEI, which has a good clinical application prospect. However, the sample size of the included studies is small and significant statistical heterogeneity still existed in the included studies, so it should be further explored and confirmed.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (No. H0517/81560132), the Supporting Project for the Foregoers of Main Disciplines of Jiangxi Province (No. 20162BCB22023), the "5511" Innovative Drivers for Talent Teams of Jiangxi Province (No. 20165BCB18018), and the Nature Science Foundation of JiangXi Province (No. 20181BAB205016).

Author contributions

Writing – original draft: Daijin Ren, Chao Zuo. Writing – review & editing: Gaosi Xu.

References

- International Diabetes Federation. IDF Diabetes Atlas. 8th edition.2017. Available from: http://www.idf.org/diabetesatlas.
- [2] Lee S-Y, Choi ME. Urinary biomarkers for early diabetic nephropathy: beyond albuminuria. Pediatr Nephrol 2015;30:1063–75.
- [3] Robert C, Stanton M. Frontiers in diabetic kidney disease: introduction. Am J Kidney Dis 2014;63:S1–2.
- [4] Reutens AT. Epidemiology of diabetic kidney disease. Med Clin North Am 2013;97:1–8.
- [5] Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997;51:2–15.
- [6] Quiroga B, Arroyo D, Arriba G. Present and future in the treatment of diabetic kidney disease. J Diabet Res 2015;2015. doi: 10.1155/2015/ 801348.
- [7] Liu ZH, Li SH, Wu Y, et al. Treatment of membranous nephropathy with Tripterygium wilfordii and steroid: a prospective randomized control trial. Chin J Nephrol Dial Transplant 2009;18:303–9.
- [8] Ji SM, Wang QW, Chen JS, et al. Clinical trial of Tripterygium wilfordii Hook F. in human kidney transplantation in China. Transplant Proc 2006;38:1274–9.
- [9] Wu wei , Yang JJ, Yang HM, et al. Multi-glycoside of Tripterygium wilfordii Hook. f. attenuates glomerulosclerosis in a rat model of diabetic nephropathy by exerting anti-microinflammatory effects without affecting hyperglycemia. Int J Mol Med 2017;40:721–30.
- [10] Ma RX, Liu LQ, Liu XM, et al. Triptolide markedly attenuates albuminuria and podocyte injury in an animal model of diabetic nephropathy. Exp Ther Med 2013;6:649–56.
- [11] Liu ZH, Chen ZH, et al. Triptolide: a potent inhibitor of NF-KB in Tlymphocytes. Acta Pharmacol Sin 2000;21:782–6.
- [12] Hong Y, Gui ZH, Cai XP, et al. Clinical efficacy and safety of tripterygium glycosides in treatment of stage IV diabetic nephropathy: a meta-analysis. De Gruyter Open 2016;11:611–7.
- [13] Zheng XY. Guidelines for Clinical Research of New Chinese Medicine Drugs (trial). Beijing: China Medical Science Press; 2002. 156.
- [14] Cai XP. ARB combined with Tripterygium glycosides in the treatment of diabetic nephropathy. J Clin Med Pract 2012;16:112–4.
- [15] Huang NC. Clinical observation of Tripterygium wilfordii combined with Irbesartan in the treatment of diabetic nephropathy with large amount of proteinuria. Jilin Med J 2010;31:5312–3.
- [16] Wang ML, Zhang C. Clinical observation of Valsartan combined with Tripterygium wilfordii in the treatment of proteinuria in type 2 diabetic nephropathy. Chin J Clin Rational Drug Use 2012;5:84–5.
- [17] Tan YS, Wang M. Clinical observation of Tripterygium wilfordii combined with Irbesartan in the treatment of diabetic nephropathy with large amount of proteinuria. Natl Med Front China 2010;5:32–3.
- [18] Song HX, Gong J, Chen W, et al. Effects of Tripterygium glycosides on urinary monocyte chemotaxis protein-1 in diabetic nephropathy patients. Chin J Integr Traditional West Med 2005;25:416–8.
- [19] Li D. Tripterygium glycosides adjuvant treatment of diabetic nephropathy: reported of 53 cases. Heilongjiang Med J 2014;38:1029–30.
- [20] Yun WF. A clincial study of Tripterygium glycosides adjuvant treatment of diabetic nephropathy. Nei Mongol J Traditional Chin Med 2014; 26:15.
- [21] Li MR. Clinical research of Tripterygium wilfordii glycosides tablets combined with Valsartan capsule in the treatment of diabetic nephropathy IV period China Health Care & nutrition. 2013; 9: 138.
- [22] Zhao RY, Tang BS, Shi XL, et al. Clinical observation on 46 cases of diabetic nephropathy treated with Tripterygium wilfordii and Valsartan. *Chin J Integr Traditional West Nephrol* 2011;12:811–3.
- [23] Chen XY. Clinical observation of Tripterygium wilfordii polyglycoside tablets combined with Benapril in the treatment of diabetic nephropathy with proteinuria. Shaanxi J Traditional Chin Med 2013;34:1016–7.

- [24] Pu Y, Zou QW, Pu. Min. Analysis of the effect of Valsartan combined with Tripterygium glycosides in the treatment of diabetic nephropathy: reported 78 cases. Jilin Med J 2013;34: 5789–91.
- [25] Xu BX. Clinical analysis of tripterygium glycosides combined with benazepril in the treatment of diabetic nephropathy. J Bethune Military Med Coll 2014;12:90–1.
- [26] Wu YP, Shi NC. Clinical observation on the effect of Valsartan combined with Tripterygium glycosides in the treatment of diabetic nephropathy stage IV. Chin Rem Clin 2018;18:753–4.
- [27] Bao HJ. Clinical observation of Benapril comined with *Tripterygium wilfordii* in the treatment of diabetic nephropathy. J Pract Diabetol 2016;12:15–7.
- [28] Zhou CL. Clinical efficacy of *Tripterygium wilfordii* combined with Valsartan in the treatment of diabetic nephropathy with massive proteinuria. For all Health 2013;7:94–5.
- [29] Wu SB, Cao ZD, Zhang W, et al. Clinical observation of *Tripterygium wilfordii* combined with Valsartan in the treatment of diabetic nephropathy with massive proteinuria. Modern J Integr Traditional Chin West Med 2012;21:394–5.
- [30] Li J. Clinical study of Tripterygium glycosides combined with Valsartan in the treatment of diabetic nephropathy. Chin Commun Doctors 2011;13:43.
- [31] Cao QS. Clinical observation on the effect of Tripterygium glycosides combined with Valsartan tablets in the treatment of diabetic nephropathy. China Prac Med 2011;5:156–7.
- [32] Xu C, Qi AR, Fu B, et al. Clinical observation on treating diabetic nephropathy during IV period with the Tripterygium glycosides tablets. Clin J Chin Med 2016;8:95–6.
- [33] Zhang HC. A clincial study of tripterygium glycosides tablets adjuvant treatment of diabetic nephropathy during IV period. China Pharmaceut 2015;24:248–9.
- [34] Yang LH. Losartan combined with tripterygium glycosides in the treatment of diabetic nephropathy during IV period. Proc Clin Med 2016;25:553.
- [35] Wang JC. Clinical study of Tripterygium glycosides combined with Irbesartan in the treatment of diabetic nephropathy. China Prac Med 2013;8:182–3.
- [36] Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.
- [37] Friedrich JO, Adhikari NKJ, Beyene J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol 2007;7:5.
- [38] Wu Y, Cui J, Bao X. Triptolide attenuate oxidative stress, NF-kB activation and multiple cytokine gene expression in murine peritoneal macrophage. Int J Mol Med 2006;17:141.
- [39] Wan YG, Sun W, Zhen YJ, et al. Multi-glycoside of *Tripterygium wilfordii* Hook. f. reduces proteinuria through improving podocyte slit diaphragm dysfunction in anti-Thy1.1 glomerulonephritis. J Ethno-pharmacol 2011;136:322–33.
- [40] Nakamura T, Fujiwara N, Sato E, et al. Renoprotective effects of various angiotensin II receptor blockers in patients with early-stage diabetic nephropathy. Kidney Blood Press Res 2010;33:213–20.
- [41] Bakris G, Burgess E, Weir M, et al. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 2008;74:364–9.
- [42] Ogawa S, Matsushima M, Mori T, et al. Identification of the stages of diabetic nephropathy at which angiotensin II receptor blockers most effectively suppress albuminuria. Am J Hypertens 2013;26: 1064–9.
- [43] Pathak JV, Dass EE. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy. Indian J Pharmacol 2015;47:148–52.